Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeoGenomics, Inc. filings document the regulatory record of an oncology diagnostics company whose common stock trades on Nasdaq under the symbol NEO. Form 8-K reports furnish quarterly and annual operating results, preliminary financial information, press release exhibits, and Regulation FD disclosures tied to the company’s clinical testing and diagnostic services business.
The company’s proxy materials cover board structure, director matters, executive compensation, equity awards, pay-versus-performance disclosures and annual meeting governance. Other material-event filings describe officer transitions, board appointments and resignations, and registered security information, including common stock par value and exchange listing details.
Key takeaways from CEO Anthony P. Zook’s Form 4 filing (NEO, filed 6 Aug 2025):
- On 06 Aug 2025 Zook executed an open-market purchase (code P) of 17,900 common shares at $5.584, raising his direct stake to 38,066 shares; he also beneficially owns 18,900 shares via a trust.
- No shares were sold or otherwise disposed.
- Derivative holdings disclosed: 8,353 options @ $14.82 (exercisable 10 Aug 2024–10 Aug 2033), 8,672 options @ $13.71 (1 Jun 2025–1 Jun 2034) and a premium-priced grant of 729,927 options @ $10.44. In addition, 421,496 restricted stock units were granted on 1 Apr 2025. All awards vest ratably over three years.
The net effect is an incremental cash purchase signalling management confidence at a price well below option strikes, while the large option/RSU package further aligns incentives but introduces future dilution risk.
NeoGenomics Director Marjorie C. Green received new equity compensation grants on June 19, 2025, consisting of:
- Stock Options: Granted 16,019 options to buy common stock at an exercise price of $6.95 per share. These options will become exercisable on June 1, 2026, and expire on June 19, 2035.
- Restricted Stock Units (RSUs): Awarded 22,964 RSUs that will vest on June 1, 2026. Once vested, these RSUs convert to common stock with no expiration date.
This Form 4 filing represents standard director compensation equity grants. The combined awards suggest continued commitment to aligning director interests with shareholders through long-term equity incentives. All securities are held directly by the reporting person.
NeoGenomics has filed a Form 3 (Initial Statement of Beneficial Ownership) announcing the appointment of Marjorie C. Green as a Director of the company, effective June 19, 2025. The filing discloses that:
- Green currently owns no securities or derivative securities of NeoGenomics
- She serves as a Director but holds no other positions (such as Officer or 10% Owner)
- The filing was submitted individually, not as part of a group
- The document was signed by Ali Olivo as Attorney-in-Fact on June 24, 2025
This Form 3 filing is a standard regulatory requirement for new company insiders under Section 16(a) of the Securities Exchange Act of 1934, establishing their initial ownership position upon assuming their role.
NeoGenomics has announced a significant board expansion and appointment in a Form 8-K filing. The company's Board of Directors has increased its size from nine to ten members with the appointment of Marjorie C. Green as a new director, effective June 19, 2025.
Key details of the appointment include:
- Ms. Green will serve until the 2026 annual meeting of stockholders or until resignation/removal
- She will receive compensation aligned with the company's existing independent director compensation program as disclosed in the 2025 proxy statement
- The appointment was publicly announced via press release on June 24, 2025
The filing, signed by EVP and General Counsel Alicia C. Olivo, includes standard regulatory disclosures and confirms that NeoGenomics is not classified as an emerging growth company. The company trades on the Nasdaq Stock Market under the symbol NEO.